Drugs / JNJ-17216498
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00424931 | Jan → Nov 2007 | narcolepsy | Alza Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-17216498 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00424931 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL3545030 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL3545030 ↗ |